【摘要】 目的:应用拉米夫定与肝毒净联合治疗慢性乙型肝炎,观察HBV标志物及HBV-DNA、ALT等指标。方法:联合治疗组用拉米夫定100 mg口服,每日1次,疗程12月,初始3个月同时给予肝毒净每次3粒,每日3次,对照组仅用拉米夫定100 mg口服,每日1次,疗程12月。结果:联合治疗组患者血清HBeAg阴转率、HBeAg抗HBe血清转换率明显高于对照组。结论:拉米夫定联合肝毒净治疗慢性乙型肝炎具有一定的临床应用价值。更多还原

【Abstract】 Objective: To investigate the changes of HBV-signs, HBV-DNA and ALT during Lamivudine and Gandujing combination therapy on patients with chronic hepatitis B.Methods:Combined application group:Lmivudine(100 mg/oral/qd/12 months) and Gandujing(3 capsules/oral/tid/for the first 3 months).Control group: Lamivudine only(100 mg/oral/qd/12 months).Results:The portion of HBeAg reduction and HBeAg seroconversion in combined application group were significantly greater than those in control group.Conclusion:It is clinically useful for Lamivudine and Gandujing combination therapy on patients with chronic hepatitis B.更多还原